Study on the Rule and Mechanism of Treating Functional Gastrointestinal Diseases From the Perspective of Liver and Spleen
NCT ID: NCT04454996
Last Updated: 2020-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2020-06-25
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Gastrointestinal Symptoms of Outpatients With Functional Gastrointestinal Diseases(FGIDs) in Grade-A Tertiary Hospitals in China
NCT04225559
Safety Study of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia
NCT01232114
Association of Functional Dyspepsia Symptom Diary Score and Other Scores Related to Functional Dyspepsia and Its Severity
NCT04953975
The Role of Intestinal Flora in the Pathogenesis of FD and the Intervention of Xiangsha Liujunzi
NCT04449887
The Effect of Multiple Medications on the Incidence of Organic Dyspepsia
NCT05524675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-erosive reflux disease test group
tong-jiang granules
This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
Non-erosive reflux disease control group
The placebo of tong-jiang granules
This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
Diarrhea-type irritable bowel syndrome test group
Chang 'an II Recipe
This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
Control group with diarrheal irritable bowel syndrome
The placebo of Chang 'an II Recipe
This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Healthy control group
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tong-jiang granules
This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
Chang 'an II Recipe
This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
The placebo of tong-jiang granules
This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
The placebo of Chang 'an II Recipe
This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Meet the diagnostic criteria of NERD syndrome of disharmony of liver and stomach and IBS-D syndrome of liver depression and spleen deficiency.
3. Aged between 18 and 70.
4. Did not take antibiotics, steroids or other hormones, Chinese herbal preparations (including oral and intravenous administration), microecological preparations or probiotics such as yogurt for nearly a week;
5. Subjects are informed and sign informed consent voluntarily;
6. Have certain reading ability.
Exclusion Criteria
2. Complicated with other organic diseases of the digestive system (such as peptic ulcer), or systemic diseases that affect the dynamics of the digestive tract (such as hyperthyroidism and diabetes);
3. Ongoing or ongoing use of drugs that may affect gastrointestinal function (antidiarrals, antidepressants, anti-anxiety drugs, intestinal microflora regulation drugs, antibiotics, etc.);
4. Those with a history of allergy to related drugs or severe food allergy used in the research.
5. The body is colonized with metal medical devices. (6) Having a pregnancy plan within three months.
\-
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xiyuan Hospital of China Academy of Chinese Medical Science
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZZ13-ZD-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.